MCID: GST047
MIFTS: 32

Gastrointestinal Neuroendocrine Tumor

Categories: Cancer diseases, Gastrointestinal diseases, Neuronal diseases

Aliases & Classifications for Gastrointestinal Neuroendocrine Tumor

MalaCards integrated aliases for Gastrointestinal Neuroendocrine Tumor:

Name: Gastrointestinal Neuroendocrine Tumor 12 15
Malignant Gastrointestinal Neuroendocrine Tumor 12
Digestive System Neuroendocrine Neoplasm 73
Digestive System Neuroendocrine Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:0050626
UMLS 73 C2987127

Summaries for Gastrointestinal Neuroendocrine Tumor

Disease Ontology : 12 A gastrointestinal system cancer that has material basis in neuroendocrine cells.

MalaCards based summary : Gastrointestinal Neuroendocrine Tumor, also known as malignant gastrointestinal neuroendocrine tumor, is related to neuroendocrine tumor and carcinoid syndrome. An important gene associated with Gastrointestinal Neuroendocrine Tumor is HDAC9 (Histone Deacetylase 9), and among its related pathways/superpathways are Neural Stem Cell Differentiation Pathways and Lineage-specific Markers and Hepatitis C and Hepatocellular Carcinoma. The drugs Everolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include liver and endothelial.

Related Diseases for Gastrointestinal Neuroendocrine Tumor

Diseases in the Gastrointestinal Neuroendocrine Tumor family:

Gastrointestinal Neuroendocrine Benign Tumor

Diseases related to Gastrointestinal Neuroendocrine Tumor via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
# Related Disease Score Top Affiliating Genes
1 neuroendocrine tumor 30.0 CHGA SST SYP
2 carcinoid syndrome 29.1 CHGA SST SYP
3 paraganglioma 29.0 CHGA SST SYP
4 liver leiomyosarcoma 10.4 CHGA SMUG1
5 esophageal neuroendocrine tumor 10.4 CHGA SYP
6 ureter small cell carcinoma 10.4 CHGA SYP
7 urinary bladder small cell neuroendocrine carcinoma 10.4 CHGA SYP
8 ovarian large-cell neuroendocrine carcinoma 10.4 CHGA SYP
9 auditory system cancer 10.4 CHGA SYP
10 acinar cell cystadenocarcinoma 10.4 CHGA SYP
11 peritoneal serous adenocarcinoma 10.4 CHGA SYP
12 primary hepatic neuroendocrine carcinoma 10.4 CHGA SYP
13 small cell carcinoma of the bladder 10.4 CHGA SYP
14 pulmonary large cell neuroendocrine carcinoma 10.4 CHGA SYP
15 chordoid meningioma 10.4 CHGA SYP
16 olfactory nerve neoplasm 10.3 CHGA SYP
17 cauda equina neoplasm 10.3 CHGA SYP
18 pancreatic serous cystadenoma 10.3 CHGA SYP
19 conventional angiosarcoma 10.3 CHGA SYP
20 pulmonary sclerosing hemangioma 10.3 CHGA SYP
21 pineocytoma 10.3 CHGA SYP
22 respiratory system benign neoplasm 10.3 CHGA SYP
23 gastric squamous cell carcinoma 10.3 CHGA SYP
24 gastric small cell carcinoma 10.3 CHGA SYP
25 subependymoma 10.3 CHGA SYP
26 pulmonary blastoma 10.3 CHGA SYP
27 ureter, cancer of 10.3 CHGA SYP
28 tanycytic ependymoma 10.3 CHGA SYP
29 retroperitoneal neuroblastoma 10.3 CDKN1A SST
30 papillary ependymoma 10.3 CHGA SYP
31 non-functioning pancreatic endocrine tumor 10.3 CHGA SYP
32 pleomorphic xanthoastrocytoma 10.3 CHGA SYP
33 sclerosing hemangioma 10.3 CHGA SYP
34 central neurocytoma 10.3 CHGA SYP
35 pancreatic cystadenocarcinoma 10.3 CHGA SYP
36 cranial nerve malignant neoplasm 10.3 CHGA SYP
37 endometrial small cell carcinoma 10.3 SMUG1 SYP
38 gastrointestinal neuroendocrine benign tumor 10.3 CHGA SST
39 cervix small cell carcinoma 10.3 CHGA SYP
40 mediastinal cancer 10.3 SMUG1 SYP
41 gastric neuroendocrine neoplasm 10.2 CHGA SST
42 olfactory neuroblastoma 10.2 CHGA SYP
43 malignant skin fibrous histiocytoma 10.2 CHGA SMUG1
44 cerebellar liponeurocytoma 10.2 CHGA SYP
45 pituitary carcinoma 10.2 CHGA SST
46 horseshoe kidney 10.2 CHGA SYP
47 glucagonoma 10.2 CHGA SST
48 granulosa cell tumor of the ovary 10.2 CHGA SYP
49 hyperinsulinemic hypoglycemia, familial, 2 10.2 CHGA SST
50 large cell neuroendocrine carcinoma 10.2 CHGA SYP

Graphical network of the top 20 diseases related to Gastrointestinal Neuroendocrine Tumor:



Diseases related to Gastrointestinal Neuroendocrine Tumor

Symptoms & Phenotypes for Gastrointestinal Neuroendocrine Tumor

Drugs & Therapeutics for Gastrointestinal Neuroendocrine Tumor

Drugs for Gastrointestinal Neuroendocrine Tumor (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 58)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Everolimus Approved Phase 3,Phase 2,Phase 1 159351-69-6 6442177
2
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
3
Sirolimus Approved, Investigational Phase 3,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
4
Octreotide Approved, Investigational Phase 3,Phase 2,Phase 1 83150-76-9 383414 6400441
5
Somatostatin Approved, Investigational Phase 3,Phase 2 38916-34-6, 51110-01-1 53481605
6
Fluorouracil Approved Phase 3 51-21-8 3385
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
9 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
10 Antifungal Agents Phase 3,Phase 2,Phase 1
11 Anti-Infective Agents Phase 3,Phase 2,Phase 1
12 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
13 Antineoplastic Agents, Hormonal Phase 3,Phase 2,Phase 1
14 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
15 Antimetabolites Phase 3
16 Antimetabolites, Antineoplastic Phase 3
17
Sunitinib Approved, Investigational Phase 2 341031-54-7, 557795-19-4 5329102
18
Bevacizumab Approved, Investigational Phase 2 216974-75-3
19
Dacarbazine Approved, Investigational Phase 2 4342-03-4 5351166
20 lanreotide Approved Phase 2 108736-35-2
21
Temozolomide Approved, Investigational Phase 2 85622-93-1 5394
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
24
Panobinostat Approved, Investigational Phase 2 404950-80-7 6918837
25 Combretastatin Investigational Phase 2 82855-09-2
26
Fosbretabulin Investigational Phase 2 222030-63-9 5351387
27 Liver Extracts Phase 2
28 Antimitotic Agents Phase 2
29 Antineoplastic Agents, Phytogenic Phase 2,Not Applicable
30 Angiogenesis Inhibitors Phase 2,Phase 1
31 Angiogenesis Modulating Agents Phase 2,Phase 1
32 Antibodies Phase 2,Phase 1
33 Antibodies, Monoclonal Phase 2,Phase 1
34 Endothelial Growth Factors Phase 2
35 Immunoglobulin G Phase 2
36 Immunoglobulins Phase 2,Phase 1
37 Mitogens Phase 2
38 Alkylating Agents Phase 2
39 Angiopeptin Phase 2
40 Antineoplastic Agents, Alkylating Phase 2
41 Hormone Antagonists Phase 2
42 Hormones Phase 2
43 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 2
44 Albumin-Bound Paclitaxel Phase 2
45 Histone Deacetylase Inhibitors Phase 2
46 tyrosine Nutraceutical Phase 2
47
Trebananib Investigational Phase 1 894356-79-7
48
Resveratrol Approved, Experimental, Investigational Not Applicable 501-36-0 445154
49 Pancreatic Polypeptide Investigational 59763-91-6
50 Analgesics Not Applicable

Interventional clinical trials:

(show all 22)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Everolimus and (STZ-5FU) Given One Upfront the Other Upon Progression in Advanced pNET Recruiting NCT02246127 Phase 3 Drug: Everolimus;STZ-5FU
2 Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery Not yet recruiting NCT03375320 Phase 3 Cabozantinib S-malate
3 Randomized Phase III of PRRT Versus Interferon Withdrawn NCT01860742 Phase 3 Interferon alpha-2b;177Lu-DOTATATE
4 A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers Completed NCT02132468 Phase 2 fosbretabulin tromethamine
5 Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization Completed NCT00434109 Phase 2 Sunitinib malate
6 Phase II Study of Everolimus Combined With Octreotide LAR to Treat Advanced GI NET Completed NCT01567488 Phase 2 Everolimus;octreotide LAR
7 Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer Completed NCT00454363 Phase 2 Pazopanib Hydrochloride
8 Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Completed NCT01010126 Phase 2 Temsirolimus
9 Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET Completed NCT02231762 Phase 2 Lanreotide Autogel 120 mg;Temozolomide (TMZ)
10 Stereotactic Body Radiation Therapy (SBRT) for Unresectable Liver Metastases Recruiting NCT02185443 Phase 2
11 Efficacy and Safety Study in Pancreatic or Midgut Neuroendocrine Tumours Having Progressed Radiologically While Previously Treated With Lanreotide Autogel® 120 mg Recruiting NCT02651987 Phase 2 Lanreotide autogel 120 mg
12 Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres Active, not recruiting NCT02859064 Phase 2 Lanreotide
13 Study of Everolimus Treatment in Newly-diagnosed Patients With Advanced Gastrointestinal Neuroendocrine Tumors Active, not recruiting NCT01648465 Phase 2 Everolimus
14 A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas Active, not recruiting NCT02215447 Phase 2 NAB paclitaxel;Carboplatin
15 Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors Active, not recruiting NCT01841736 Phase 2 Pazopanib Hydrochloride
16 Study of Panobinostat in Patients With Neuroendocrine Tumors Terminated NCT00985946 Phase 2 panobinostat (LBH589)
17 Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Completed NCT01204476 Phase 1 Everolimus;Octreotide Acetate
18 Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Completed NCT01548482 Phase 1 Temsirolimus
19 Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors Unknown status NCT00454376
20 Quality-Of-Life QLQ-GINET21 Questionnaire In The Treatment Of Patients With Gastrointestinal Neuroendocrine Tumours Completed NCT02853422
21 Everolimus TDM to Predict Long Term Toxicity Recruiting NCT03033186
22 A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors Active, not recruiting NCT01476592 Not Applicable

Search NIH Clinical Center for Gastrointestinal Neuroendocrine Tumor

Genetic Tests for Gastrointestinal Neuroendocrine Tumor

Anatomical Context for Gastrointestinal Neuroendocrine Tumor

MalaCards organs/tissues related to Gastrointestinal Neuroendocrine Tumor:

41
Liver, Endothelial

Publications for Gastrointestinal Neuroendocrine Tumor

Articles related to Gastrointestinal Neuroendocrine Tumor:

(show all 20)
# Title Authors Year
1
Nomogram predicting the risk of recurrence after curative-intent resection of primary non-metastatic gastrointestinal neuroendocrine tumors: An analysis of the U.S. Neuroendocrine Tumor Study Group. ( 29448303 )
2018
2
Resection of the Primary Gastrointestinal Neuroendocrine Tumor Improves Survival with or without Liver Treatment. ( 29746336 )
2018
3
Peripancreatic paraganglioma mimics pancreatic/gastrointestinal neuroendocrine tumor on fine needle aspiration: Report of two cases and review of the literature. ( 28560856 )
2017
4
Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors. ( 29142475 )
2017
5
Gastrointestinal neuroendocrine tumor with unresectable liver metastases: an example of multimodal therapeutic approach. ( 26256906 )
2015
6
Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. ( 24114056 )
2013
7
Heat shock protein 90 is a promising target for effective growth inhibition of gastrointestinal neuroendocrine tumors. ( 22246317 )
2012
8
Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. ( 21431978 )
2011
9
Molecular and functional characterization of non voltage-operated Ca entry in gastrointestinal neuroendocrine tumor cells. ( 21383891 )
2010
10
Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. ( 18987169 )
2009
11
Novel targets for the treatment and palliation of gastrointestinal neuroendocrine tumors. ( 18516757 )
2008
12
New developments in the treatment of gastrointestinal neuroendocrine tumors. ( 17430688 )
2007
13
Gastrointestinal neuroendocrine tumors: a role for targeted therapies? ( 17639038 )
2007
14
Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells. ( 17158768 )
2006
15
The significance of CD44 expression in gastrointestinal neuroendocrine tumors. ( 16001632 )
2005
16
Circulating ghrelin levels in patients with pancreatic and gastrointestinal neuroendocrine tumors: identification of one pancreatic ghrelinoma. ( 12843152 )
2003
17
Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms. ( 10561168 )
1999
18
Definition of the role of somatostatin receptor scintigraphy in gastrointestinal neuroendocrine tumor localization. ( 9825476 )
1997
19
Serum neuron-specific enolase in diagnosis and follow-up of gastrointestinal neuroendocrine tumors. ( 1290031 )
1992
20
Recent advances in carcinoids and gastrointestinal neuroendocrine tumors. ( 2043691 )
1991

Variations for Gastrointestinal Neuroendocrine Tumor

Expression for Gastrointestinal Neuroendocrine Tumor

Search GEO for disease gene expression data for Gastrointestinal Neuroendocrine Tumor.

Pathways for Gastrointestinal Neuroendocrine Tumor

Pathways related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.85 CD44 SYP
2 10.33 CD44 CDKN1A

GO Terms for Gastrointestinal Neuroendocrine Tumor

Biological processes related to Gastrointestinal Neuroendocrine Tumor according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to organonitrogen compound GO:0010243 8.62 CDKN1A SST

Sources for Gastrointestinal Neuroendocrine Tumor

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....